Valo Health, a Boston, MA-based technology company focused on improving the drug discovery and development process, received a $110m investment from Koch Disruptive Technologies (KDT).
The company also held the final closing of its Series B round at $300m, which brings the overall funding raised to date to over $450m.
The company intends to use the funds for scaling the Opal Computational Platform, working capital, and other general purposes.
Led by David Berry, founder and CEO, Valo Health provides the Opal Computational PlatformTM, an integrated platform that combines machine learning-driven computational capabilities and patient data to develop therapeutic programs across major disease areas.
Using Opal, Valo scientists have been able to identify associations between genetic markers and disease, which identify the specific changes in gene activity with an initial focus on oncology, neurodegenerative, and cardiovascular diseases.
Founded by Flagship Pioneering, the company also has has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and in Branford, CT.